Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease.

JAMA cardiology - 1 May 2025

Wang Wenxiu, Li Rui, Song Zimin, Huang Ninghao, Huang Tao, Hua Xinwei, Tang Yi-Da

Abstract excerpt

Importance: Despite substantial progress in low-density lipoprotein cholesterol (LDL-C)-lowering strategies, residual cardiovascular risk remains. Apolipoprotein C3 (APOC3) has emerged as a novel target for lowering triglycerides. Multiple clinical trials of small-interfering RNA therapeutics targeting APOC3 are currently underway. Objective: To investigate whether genetically predicted lower APOC3 is associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Apolipoprotein C-III
Share to Cholesterol, LDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coronary Disease

Share to Mendelian Randomization Analysis

Share to Polymorphism, Single Nucleotide

Share to Risk Factors

Share to United Kingdom

Source

Open in PubMed Open full text

Identifiers

PMID: 40105833
DOI: 10.1001/jamacardio.2025.0195
PMCID: PMC11923777

Genes

APOC3
PCSK9
HMGCR
C3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease.PMID 40105833Read ↗

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention.Semantic proximity Read ↗

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases preventionSemantic proximity Read ↗

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read ↗

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read ↗

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.Semantic proximity Read ↗

Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study.Semantic proximity Read ↗

The Genetic Revolution in Cardiometabolic Disease: A Review of Novel RNA and Gene‐Editing Therapies Targeting APOC3, ANGPTL3, and Lp(a)Semantic proximity Read ↗

APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups.Semantic proximity Read ↗

Loss-of-function mutations in APOC3, triglycerides, and coronary disease.Semantic proximity Read ↗

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic riskSemantic proximity Read ↗

Management and Consequences of Genotype-Positive Familial Hypercholesterolemia.Semantic proximity Read ↗

Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.